NCT03564782: Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer

NCT03564782
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active central nervous system metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT03564782

Comments are closed.

Up ↑